Treating neutropenia depends on what’s causing it and how low your neutrophil count has dropped. A normal neutrophil count ranges from about 1,500 to 8,000 cells per microliter of blood. When your count falls below 1,500, you have neutropenia, and treatment can range from simple monitoring to immediate hospitalization with antibiotics, growth factor injections, or even a stem cell transplant.
Severity Levels and What They Mean
Neutropenia is classified by your absolute neutrophil count (ANC), which you’ll see on a standard blood test. Mild neutropenia (ANC between 1,000 and 1,500) often doesn’t need aggressive treatment. Many people with mild neutropenia caused by a medication or recent viral infection are simply monitored with blood counts several times per week for six to eight weeks to see if the count recovers on its own.
Moderate neutropenia (ANC 500 to 1,000) puts you at increased infection risk, and your care team will watch you more closely. Severe neutropenia, sometimes called agranulocytosis, means your ANC has dropped below 500. At this level, your body has very limited ability to fight off bacteria and fungi, and even a minor infection can escalate quickly. If you develop a fever (typically 100.4°F or higher) while severely neutropenic, that’s a medical emergency requiring immediate hospitalization and broad-spectrum antibiotics.
How Febrile Neutropenia Is Treated
Febrile neutropenia, a fever during a period of very low neutrophil counts, is the most urgent scenario. Guidelines from the Infectious Diseases Society of America are clear: all patients who present with fever and neutropenia should receive antibiotics swiftly, covering both major categories of bacteria. The goal is to start treatment before a specific infection is even identified, because waiting for lab results can be dangerous when your immune defenses are this low.
Not everyone with febrile neutropenia needs to stay in the hospital, though. Doctors use a scoring system called the MASCC risk index to figure out who can safely go home with oral antibiotics. The score (out of a maximum 26 points) accounts for factors like blood pressure, age, whether you were already hospitalized when the fever started, whether you’re dehydrated, and the overall severity of your symptoms. A score of 21 or higher identifies you as lower risk, and several major oncology organizations endorse outpatient treatment for these patients. A score below 21 means you’re at higher risk for serious complications and will likely need intravenous antibiotics in the hospital.
For patients expected to have extremely low counts (under 100 cells per microliter) for more than seven days, preventive antifungal medications are also recommended alongside antibiotics, since fungal infections become a real threat during prolonged severe neutropenia.
Growth Factor Injections
The most common treatment for neutropenia, especially when it’s caused by chemotherapy, is a class of medication called granulocyte colony-stimulating factors (G-CSF). These drugs stimulate your bone marrow to produce more neutrophils and also help existing neutrophils mature faster and survive longer.
The short-acting version is given as a daily injection under the skin, usually starting the day after a chemotherapy session. The long-acting version requires just one injection per chemotherapy cycle, given as a 6 mg dose at least 24 hours after chemo. It’s injected in the upper arm or abdomen and works over a longer period, which means fewer shots overall. For children, the dose is adjusted by weight.
These injections are effective, but they come with a well-known side effect: bone pain. About 20% of cancer patients on the daily version experience it, while 25% to 38% of those on the long-acting version report bone pain. Interestingly, healthy bone marrow donors who receive G-CSF have even higher rates, between 52% and 84%, likely because their marrow responds more vigorously. The pain is usually managed with over-the-counter pain relievers. One clinical trial found that naproxen specifically reduced both the severity and duration of G-CSF-related bone pain. If those don’t work, antihistamines, stronger pain medications, or a dose reduction are secondary options.
Treating the Underlying Cause
When neutropenia is caused by a medication, the fix is often straightforward: stop or switch the offending drug, and the count usually recovers within one to three weeks. Certain chemotherapy regimens, antibiotics, antithyroid drugs, and psychiatric medications are common culprits.
Autoimmune neutropenia is a different challenge. In this condition, your immune system produces antibodies that destroy your own neutrophils. In children, autoimmune neutropenia often resolves on its own. In adults, it’s more frequently linked to an underlying autoimmune disease and may require immunosuppressive therapy. Treatment options include corticosteroids, intravenous immunoglobulin, or targeted therapies depending on the severity. For a specific subtype linked to a slow-growing blood cancer called LGL leukemia, treatment typically involves immunosuppressive agents to reduce the abnormal immune cells that are driving the neutropenia. G-CSF can be added when patients experience recurrent infections or their ANC drops below 200, though results vary.
Congenital Neutropenia and Stem Cell Transplant
Some people are born with genetic mutations that cause chronically low neutrophil counts, a group of conditions called congenital or severe congenital neutropenia. Most of these patients are started on G-CSF early in life and remain on it long-term. For many, daily injections keep their counts high enough to prevent serious infections.
A stem cell transplant (also called a bone marrow transplant) becomes the recommended option in two main situations: when a patient doesn’t respond to G-CSF at all, or when they develop signs of a pre-cancerous bone marrow condition or leukemia, which is a known long-term risk of congenital neutropenia. Patients who need very high doses of G-CSF with poor neutrophil response are also strongly considered for transplant, as this pattern carries higher risks over time.
When transplant is performed before any malignant transformation, outcomes are encouraging. Overall survival across published studies is about 89%, with the best results (95% survival) seen in patients who have a fully matched related donor. Umbilical cord blood transplants also show strong outcomes at 93% survival. If a patient has already developed leukemia before transplant, survival drops significantly, to about 36%, which is one reason doctors monitor congenital neutropenia patients closely and consider transplant early when risk factors are present.
Diet and Infection Prevention
For decades, patients with neutropenia were put on a “neutropenic diet” that eliminated raw fruits, vegetables, and other fresh foods thought to carry bacteria. This practice is falling out of favor. A meta-analysis of six studies involving over 1,100 patients found that a restrictive neutropenic diet did not reduce infection rates or mortality compared to a standard diet following basic FDA food safety guidelines. The results held for both children and adults.
What does matter is standard food safety: washing produce thoroughly, cooking meats to proper temperatures, avoiding cross-contamination, and steering clear of obviously high-risk items like unpasteurized dairy. Beyond diet, practical infection prevention during periods of low counts includes frequent handwashing, avoiding crowds and people who are sick, and keeping up with any recommended preventive medications your care team prescribes.
Monitoring During Treatment
If you’re receiving chemotherapy, your care team will check your blood counts at intervals tailored to your specific treatment regimen. There’s no single universal schedule. The timing depends on which drugs you’re receiving, how your body has responded in previous cycles, and national guidelines for your particular regimen. Some protocols call for blood work weekly, others more or less frequently.
Your treatment plan should include clear parameters for what happens if your counts drop too low, including whether a dose will be delayed, reduced, or supported with growth factor injections. If you’re being monitored for mild neutropenia without an obvious cause, expect blood draws several times a week initially, tapering off as your care team gets a clearer picture of whether your counts are recovering or trending downward.